

Prior Authorization Form

NOTE: Refer to the Provider Manual for additional services requiring **Prior Authorization**



Fax Form To: Grand Rapids – 616 942-0024 Holland – 616 392-7626 ASO – 616 395-4090 Traverse City – 231 932-9505 Farmington Hills – 800 289-6744

Gene Expression Analysis:

Breast Cancer Treatment Assessment with Oncotype DX™ (policy #91540)

Member

Last Name: _____ First Name: _____
ID #: _____ DOB: _____
Plan/Product Type: EPO HMO POS SF-POS PPO Medicaid Medicare
Primary Care Physician: _____ PCP Phone: _____ PCP Fax: _____
Has PCP been notified of request? Yes No Is this authorization related to: Work Injury Motor Vehicle Accident

Requested By:

Provider Name: _____ Phone: _____ Fax: _____
Address: _____ Contact Name: _____
Date of Request: _____

Directed To:

Provider Name: _____ Facility: _____
Address: _____ Address: _____
Provider Phone: _____ Fax: _____ Facility Phone: _____ Fax: _____
Contact Name: _____ Contact Name: _____
Date of Service _____

Oncotype DX™ (21-gene panel; Genomic Health) is considered medically appropriate to assess the need for adjuvant chemotherapy in women with recently diagnosed breast cancer when **all** of the following criteria are met:

- Yes No Breast tumor is stage 1 or stage 2.
- Yes No Breast tumor is estrogen-receptor positive.
- Yes No Breast tumor is HER2-receptor negative, or breast tumor is HER2 receptor positive and less than 1 cm in diameter.
- Yes No There is no evidence of metastatic breast cancer, and the patient is axillary-node negative.
- Yes No The patient is a candidate for possible adjuvant chemotherapy (i.e., chemotherapy is not precluded due to other factors).
- Yes No Member and physician (prior to testing) have discussed the potential results of the test and agree to use the results to guide therapy (i.e., member will forgo adjuvant chemotherapy if Oncotype Dx™ score is low).

Women with an intermediate recurrence score are encouraged to consider participating in the TAILORx trial. The TAILORx trial is designed primarily to evaluate the effect of chemotherapy on those with a recurrence score of 11 to 25. Women participating in this trial who are in this group will be randomly assigned to receive adjuvant hormonal therapy, with or without chemotherapy. The TAILORx seeks to determine if the Oncotype DX™ test will be helpful in future treatment planning for this group.

For patients choosing chemotherapy for an intermediate risk score, the clinical rationale must be provided for treatment since chemotherapy is still of unproven benefit.